Odyssey's OD-001 Hits Phase 2a Endpoint in Ulcerative Colitis, 20 mg BID Dose Selected
ODTX sits 18% above its 52-week low of $15.1.
Summary
Odyssey reported completed induction analyses from the open-label Phase 2a trial of OD-001 in moderate-to-severe ulcerative colitis, with the drug meeting its primary endpoint and 20 mg twice daily chosen as the projected lowest maximally efficacious dose. Biomarker and transcriptomic correlations back the mechanism, and the 12-week safety profile showed no serious adverse events. This is the clinical readout the company flagged in its August 4 8-K and Q2 filing, where R&D spend had climbed to $36.2M largely on the OD-001 program; the $433.1M cash balance funds the next stage into H2 2028. The caveat is that the trial was open-label with no placebo control, so the effect size still needs randomized confirmation. Next up are randomized, double-blind Phase 2b and combination studies, with key data now pointed at 2H 2027.
At the time of this announcement, ODTX was trading at $17.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $869.9M. The 52-week trading range was $15.10 to $29.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.